Stock ALPRE PREDILIFE
Add to a list
To use this feature you must be a member
Log inSign up

Financials PREDILIFE

Equities

ALPRE

FR0010169920

Biotechnology & Medical Research

Real-time Euronext Paris
Other stock markets
 08:00:29 27/06/2024 BST 		5-day change 1st Jan Change
6 EUR 0.00% Intraday chart for PREDILIFE +8.11% +5.26%
04-24 Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Predilife: a project accredited by Finance Innovation CF

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 25.74 21.89 25.27 25.17 19.39 20.75
Enterprise Value (EV) 1 25.76 22.99 24.77 27.38 22.91 24.75
P/E ratio -10.9 x -11.2 x -11.2 x -7.4 x -5.32 x -5 x
Yield - - - - - -
Capitalization / Revenue 1,525 x 957 x 490 x 177 x 67.2 x 65.3 x
EV / Revenue 1,525 x 1,005 x 480 x 193 x 79.4 x 77.9 x
EV / EBITDA -11.1 x -9.64 x -10.1 x -7.84 x -6.6 x -6.46 x
EV / FCF -18.9 x -11.6 x -18.1 x -10.8 x -10.7 x -8.92 x
FCF Yield -5.29% -8.61% -5.51% -9.25% -9.31% -11.2%
Price to Book -2,128 x -30.6 x 35 x -16.1 x -3.71 x -2.32 x
Nbr of stocks (in thousands) 2,753 2,753 3,486 3,648 3,645 3,641
Reference price 2 9.350 7.950 7.250 6.900 5.320 5.700
Announcement Date 30/04/19 30/04/20 28/09/21 29/04/22 24/04/24 24/04/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.0169 0.0229 0.0516 0.1421 0.2886 0.3178
EBITDA 1 -2.318 -2.384 -2.455 -3.491 -3.472 -3.833
EBIT 1 -2.355 -2.423 -2.487 -3.52 -3.504 -3.846
Operating Margin -13,949.18% -10,592.22% -4,822.89% -2,477.67% -1,214.16% -1,210.27%
Earnings before Tax (EBT) 1 -2.621 -2.474 -2.541 -3.709 -3.911 -4.456
Net income 1 -2.371 -2.102 -2.251 -3.414 -3.655 -4.224
Net margin -14,041.24% -9,191.15% -4,364.07% -2,402.69% -1,266.31% -1,329.2%
EPS 2 -0.8600 -0.7124 -0.6445 -0.9327 -1.000 -1.140
Free Cash Flow 1 -1.362 -1.98 -1.365 -2.534 -2.132 -2.776
FCF margin -8,065.58% -8,656.2% -2,647.16% -1,783.39% -738.89% -873.49%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 30/04/19 30/04/20 28/09/21 29/04/22 24/04/24 24/04/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.01 1.1 - 2.21 3.52 4
Net Cash position 1 - - 0.5 - - -
Leverage (Debt/EBITDA) -0.006397 x -0.461 x - -0.634 x -1.014 x -1.043 x
Free Cash Flow 1 -1.36 -1.98 -1.37 -2.53 -2.13 -2.78
ROE (net income / shareholders' equity) 364% 542% 10,566% 809% 108% 59.1%
ROA (Net income/ Total Assets) -88.8% -82.8% -57.1% -54.6% -50.3% -52.6%
Assets 1 2.669 2.538 3.942 6.254 7.269 8.03
Book Value Per Share 2 -0 -0.2600 0.2100 -0.4300 -1.430 -2.460
Cash Flow per Share 2 0.5400 0.1000 0.9000 0.7700 1.020 0.6800
Capex 1 0.19 0.02 0.02 0 0.03 0.04
Capex / Sales 1,113.8% 95.33% 30.41% 2.37% 9.35% 13.35%
Announcement Date 30/04/19 30/04/20 28/09/21 29/04/22 24/04/24 24/04/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PREDILIFE Stock PREDILIFE
+5.26% 23.71M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-40.31% 8.15B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
+8.65% 3.6B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
-0.25% 2.27B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-24.56% 1.9B
VERACYTE, INC. Stock Veracyte, Inc.
-18.21% 1.72B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+5.95% 922M
CAREDX, INC Stock CareDx, Inc
+16.75% 731M
SEEGENE, INC. Stock Seegene, Inc.
-10.48% 679M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
-0.60% 288M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. ALPRE Stock
  4. Financials PREDILIFE